Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PX-866||Sonolisib|PX866||PI3K Inhibitor (Pan) 38||Sonolisib (PX-866) is a PI3K inhibitor, which inhibits the activation of the PI3K/Akt signaling pathway, thereby inhibiting cancer cell motility and growth (PMID: 17766839).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA wild-type||Advanced Solid Tumor||sensitive||PX-866||Phase I||Actionable||In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).||22693357|
|Unknown unknown||prostate cancer||not applicable||PX-866||Phase II||Actionable||In a Phase II trial, Sonolisib (PX-866) treatment was tolerated, resulted in a partial response in 11% (2/18) and stable disease in 56% (10/18) of evaluable patients with recurrent or metastatic castration-resistant prostate cancer, PSA response was observed in 2% (1/43) of evaluable patients, and 32.6% (14/43) of all patients were progression-free at 12 weeks (PMID: 31056399).||31056399|
|PIK3CA mutant||Advanced Solid Tumor||sensitive||PX-866||Phase I||Actionable||In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).||22693357|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|